Skip to main content
SpringerLink
Log in

Certolizumab Pegol

In Crohn’s Disease

  • Adis Drug Profile
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

▴ Certolizumab pegol is a pegylated humanized Fab′ fragment of an anti-tumor necrosis factor-α (TNFα) monoclonal antibody, which binds with high affinity to both membrane-bound and soluble TNFα and demonstrates high neutralizing potency for these factors.

▴ The elimination half-life of certolizumab in humans has been extended to ≈2 weeks through pegylation, allowing subcutaneous administration of this agent once every 4 weeks.

▴ Subcutaneous certolizumab pegol 400mg once every 4 weeks (with an additional 400mg dose at week 2) was effective as induction and maintenance therapy in patients with moderate to severe Crohn’s disease in whom baseline serum C-reactive protein levels were ≥10 mg/L, according to data from two well designed, randomized phase III trials.

▴ Certolizumab pegol was, in general, well tolerated, and adverse events associated with the drug were of a mild to moderate nature; no instances of lupus were reported in any of the trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Anon. Countering Crohn’s disease with Cimzia: novel TNF-α blocker close to market. Pharm Diag Innovation 2005; 3 (8): 6-9

  2. Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 2005; 5(1): 10–8

    PubMed  Google Scholar 

  3. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005 Sep; 129(3): 807–18

    Article  PubMed  CAS  Google Scholar 

  4. Feagan B, Rutgeerts P, Schreiber S, et al. Low baseline CRP correlates with a high placebo remission rate in Crohn’s disease (CD) clinical trial at 12 weeks [abstract no. M1092]. Gastroenterology 2005; 128Suppl. 2: 307

    Google Scholar 

  5. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004 Sep; 10(5): 661–5

    Article  PubMed  Google Scholar 

  6. Weir N, Athwal D, Brown D, et al. A new generation of high-affinity humanized PEGylated Fab′ fragment anti-tumor necrosis factor-alpha monoclonal antibodies. Therapy 2006; 3(4): 535–45

    CAS  Google Scholar 

  7. US Food and Drug Administration. FDA Approves new treatment For Crohn’s disease [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01572.html [Accessed 2007 May 15]

  8. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002 Oct; 41(10): 1133–7

    Article  CAS  Google Scholar 

  9. Fossati G, Nesbitt A. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol 2005; 100Suppl. 9: 298–9

    Google Scholar 

  10. Gramlick G, Fossati G, Nesbitt A. Neutralization of soluble and membrane tumor necrosis factor-α (TNF-α) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-α receptor-specific bioassays. Gastroenterology 2006; 130Suppl. 2: A–697

    Google Scholar 

  11. Gramlick G, Fossati G, Henry A, et al. Assessment of the affinity for soluble TNF and the neutralising potency against soluble and membrane TNF of the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab. Ann Rheum Dis 2006; 65Suppl. II: 456

    Google Scholar 

  12. Vetterlein OM, Kopotsha T, Nesbitt AM, et al. Antibodies to infliximab in patients with Crohn’s disease do not cross-react with certolizumab pegol [abstract no. MON-G-261]. Gut 2006; 55 (Suppl. V): A133. Plus poster presented at the 14th United European Gastroenterology Week; 2006 Oct 21–25; Berlin

  13. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase III study (PRECiSE I) [abstract no. 745]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): 107. Plus oral presentation presented at Digestive Disease Week; 2006 May 20–25; Los Angeles

  14. Schreiber S, Feagan B, Hanauer SB, et al. Safety and tolerability of subcutaneous certolizumab pegol in active Crohn’s disease: results from two phase III studies (PRECiSE program) [abstract no. 1126]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): 479. Plus poster presented at Digestive Disease Week; 2006 May 20–25; Los Angeles

  15. Baker M, Stringer F, Stephens, S. Pharmacokinetic properties of the anti-TNF agent certolizumab pegol [abstract no. THU0195]. Ann Rheum Dis 2006; (65 Suppl. 2): 175. Plus poster presented at the Annual European Congress of Rheumatology; 2006 Jun 21–24; Amsterdam

  16. Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab pegol, a pegylated Fab′ fragment of a humanised anti-tnf monoclonal antibody, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study (PRECISE 2) [abstract no. SAT0168]. Ann Rheum Dis 2006; 65Suppl. II: 500

    Google Scholar 

  17. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989 Mar; 96(3): 804–10

    PubMed  CAS  Google Scholar 

  18. Rutgeerts P, Fedorak R, Schreiber S, et al. CDP870, a pegylated humanized anti-TNF antibody fragment, improves quality of life in patients with moderate to severe Crohn’s disease [abstract no. T1306]. Gastroenterology 2004 Apr; 126(4 Suppl. 2): A–466

    Google Scholar 

  19. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther 2004 Dec; 20(11–12): 1337–46

    Article  PubMed  CAS  Google Scholar 

  20. Feagan B, Coteur G, Keninger DL, et al. Sustained improvement in health-related quality of life following certolizumab pegol 400mg every 4 weeks in patients with crohn’s disease: data from PRECiSE 2 [abstract no. MON-G-219]. Gut 2006; 55 (Suppl. V): A124. Plus poster presented at the 14th United European Gastroenterology Week; 2006 Oct 21–25; Berlin

  21. Feagan B, Coteur G, Keninger DL, et al. The burden of Crohn’s disease on patients-reported health status was relieved following maintenance treatment with certolizumab pegol 400mg every 4 weeks: data from PRECiSE 2 [abstract no. MON-G-220]. Gut 2006; 55 (Suppl. V): A124. Plus poster presented at the 14th United European Gastroenterology Week; 2006 Oct 21–25; Berlin

  22. Feagan B, Brown M, Gerlier L, et al. The effects of certolizumab pegol on work productivity and daily activities of Crohn’s disease patients: data from PRECiSE 2 [abstract no. MON-G-291]. Gut 2006; 55 (Suppl. V): A139. Plus poster presented at the 14th United European Gastroenterology Week; 2006 Oct 21–25; Berlin

  23. Schreiber S, Colombel JF, Panes J, et al. Recent-onset Crohn’s disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: results from an analysis of the PRECiSE 2 phase III study [abstract no. MON-G-255]. Gut 2006; 55 (Suppl V): A131. Plus poster presented at the 14th United European Gastroenterology Week; 2006 Oct 21–25; Berlin

  24. Schreiber S, Winter T, Innes A, et al. Safety of CDP870, a pegylated humanised anti-TNF antibody fragment, in Crohn’s disease. Gut 2003 Nov; 52Suppl. 6: 215

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Stephanie K.A. Blick & Monique P. Curran

Authors
  1. Stephanie K.A. Blick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monique P. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanie K.A. Blick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blick, S.K., Curran, M.P. Certolizumab Pegol. BioDrugs 21, 195–201 (2007). https://doi.org/10.2165/00063030-200721030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200721030-00006

Keywords

Search

Navigation